Results 71 to 80 of about 18,162 (243)
Resistance to novel drug classes [PDF]
, 2009 Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS: Integrase inhibitors and CCR5
Calvez, V. +3 more
core +1 more source
Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.ABSTRACT Introduction Migrants living with HIV often face high mobility, vulnerability and limited baseline information on HIV‐1 genotype or treatment history. We aimed to assess the effectiveness and persistence of long‐acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) among migrants in Spain. Methods This multicentre cohort study across 58
Jara Llenas‐García +62 more
wiley +1 more source
Modern antiretroviral regimens
Медицинский совет, 2016 The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and ...
A. V. Kravchenko
doaj +1 more source
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Infection and Drug Resistance, 2010 Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj
Brief Histories of Retroviral Integration Research and Associated International Conferences
VirusesThe field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj +1 more source
HIV Medicine, Volume 27, Issue 4, Page 498-512, April 2026.Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre +2 more
wiley +1 more source
Are new antiretroviral treatments increasing the risks of clinical obesity?
Journal of Virus Eradication, 2019 There is growing evidence that the use of integrase inhibitors could lead to statistically significant increases in body weight and even clinical obesity, although it is unclear whether these changes are clinically significant.
Andrew Hill, Laura Waters, Anton Pozniak
doaj +1 more source
Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms
British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 830-839, March 2026.Aim To characterize pharmacokinetic changes of sertraline and its metabolite during pregnancy and postpartum, and their relationship to maternal postpartum depressive symptoms. Methods This was a prospective observational, longitudinal study of pregnant women with a major depressive disorder treated with sertraline (N = 185 women, 205 pregnancies ...
Sílvia M. Illamola +8 more
wiley +1 more source
Retrovirology, 2011 Background HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for HIV-2-infected patients are more limited than for HIV-1.
Damond Florence +7 more
doaj +1 more source
A two week regimen of high dose integrase inhibitors does not cause nephrotoxicity in mice [PDF]
, 2015 Background The integrase inhibitors, raltegravir and dolutegravir, are nucleoside reverse transcriptase inhibitor-sparing agents which may be used as part of first-line antiretroviral therapy for HIV.
Dagher, Pierre C. +6 more
core +1 more source